Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Clinical Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus

NCT06530849 is registered in ClinicalTrials.gov with Gracell Biotechnologies (Shanghai) Co., Ltd. as lead sponsor.

NCT NCT06530849
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06530849 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Clinical Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus
Lead sponsor
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
August 22, 2024
Completion date
February 1, 2027
Enrollment
20 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

refractory systemic lupus erythematosus